The Claim
Subcutaneous administration of PCSK9 inhibitors evolocumab or alirocumab every 2 to 4 weeks reduces low-density lipoprotein (LDL) cholesterol by approximately 60% in diverse patient populations, including individuals on statin therapy, those with familial hypercholesterolemia, and patients with statin intolerance.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you take certain cholesterol-lowering shots like evolocumab or alirocumab every few weeks, they can cut your 'bad' cholesterol by about 60%, even if you're already on cholesterol pills, have a genetic form of high cholesterol, or can't handle statins.
See the scientific wording
Treatment with the PCSK9 inhibitors evolocumab or alirocumab reduces LDL cholesterol by approximately 60% across diverse patient populations, including those on statins, with familial hypercholesterolemia, or with statin intolerance, when administered subcutaneously every 2 to 4 weeks.
What the research says
1 studyStudy: PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
The study looked at the same cholesterol drugs and how they’re given, and it found they lower bad cholesterol by about 60%, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.